In Scotland, rare diseases are already managed on a pan-Scotland basis, largely through genetic services - which are subject to ongoing enhancement following on from the Calman review (2006) with £4.6 million per annum recurring investment over three years - and through access to treatments via services commissioned by National Services Division.